Loading
This study tests a PARP inhibitor; the registry reports that it is recruiting.
The registry lists NCT07590934 as recruiting, last updated 2026-08-27. Enrolment is 152 planned participants, an estimate. Interventions: AZD2265 (FPI-2265), Palacaparib (AZD9574), Docetaxel, AZD2287 (Imaging agent). Primary measures include Part A: Number of participants with treatment-emergent adverse events (TEAEs)including serious adverse events (SAEs), treatment-related AEs (TRAEs) and adverse events of special interests (AESIs); Part A: Number of participants with dose limiting toxicities (DLTs). No results are posted in the registry; this does not exclude separate publications.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Palacaparib, PARP, AstraZeneca, Prostate cancer.
Shares FPI-2265, AstraZeneca, Prostate cancer.
Shares FPI-2265, AstraZeneca, Prostate cancer.
Shares Palacaparib, PARP, AstraZeneca.
Shares FPI-2265, AstraZeneca, Prostate cancer.
Shares Palacaparib, PARP, AstraZeneca.
Shares PARP, AstraZeneca, Prostate cancer.
Shares PARP, AstraZeneca, Prostate cancer.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/